Progression patterns and site‐specific responses in advanced gastric cancer patients treated with nivolumab

BACKGROUND: While the efficacy of immune checkpoint inhibitors (ICIs) reportedly varies among metastatic sites and progression patterns (classified as systemic progression [SP] or mixed progression [MP]), the clinical efficacy of ICIs against gastric cancer remains unclear. The response to nivolumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Kadono, Toru, Iwasa, Satoru, Nagashima, Kengo, Oshima, Kotoe, Yamamoto, Shun, Hirano, Hidekazu, Okita, Natsuko, Shoji, Hirokazu, Honma, Yoshitaka, Takashima, Atsuo, Kato, Ken, Ushijima, Toshikazu, Boku, Narikazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166927/
https://www.ncbi.nlm.nih.gov/pubmed/36789624
http://dx.doi.org/10.1002/cam4.5689

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166927/
https://www.ncbi.nlm.nih.gov/pubmed/36789624
http://dx.doi.org/10.1002/cam4.5689

Ejemplares similares